Strategies to deal with dacomitinib/dacomitinib resistance

Dacomitinib/Dacomitinib (Dacomitinib), as a targeted therapeutic agent for non-small cell lung cancer, can effectively combat epidermal growth factor receptor (EGFR) mutations, thereby curbing the growth and spread of tumors. However, as treatment progresses, some patients may develop resistance to dacomitinib, which means that the drug's ability to control tumors decreases. This situation often results from genetic changes in tumor cells or adjustments in signaling pathways, which results in the weakening of the binding ability of drugs to targets or the proliferation of tumor cells is no longer inhibited.

When faced with the problem of resistance to dacomitinib, patients first need to have detailed communication with the medical team. The medical team will tailor a new treatment plan based on the patient's specific condition. This may include switching to other types of EGFR inhibitors or exploring new anti-cancer drugs to find treatments that still have an effect on the patient's tumor.

For patients with locally advanced or metastatic non-small cell lung cancer, especially those carryingEGFR mutations L858R or del19, drugs such as afatinib, gefitinib or erlotinib may become new treatment options. For different EGFR mutations, individualized treatment is particularly important, which requires doctors to adjust treatment plans according to the specific conditions of the patient. For example, drug therapy may include afatinib or in combination with other drugs such as cisplatin or carboplatin.

In addition, participating in clinical studies targeting drug resistance is also an avenue worth exploring. These studies often explore innovative treatments or drug combinations that could bring new treatment opportunities to patients. Patients should maintain a positive attitude when facing the challenge of dacomitinib resistance.